TRCT
ALNY icon

Tower Research Capital (TRC)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.19M Buy
9,627
+3,786
+65% +$1.29M 0.08% 245
2025
Q4 		$2.32M Buy
5,841
+4,304
+280% +$1.9M 0.06% 296
2025
Q3 		$701K Buy
1,537
+1,473
+2,302% +$600K 0.02% 663
2025
Q2 		$20.9K Sell
64
-1,319
-95% -$365K ﹤0.01% 3655
2025
Q1 		$367K Sell
1,383
-3,998
-74% -$1.03M 0.01% 1027
2024
Q4 		$1.27M Buy
5,381
+4,840
+895% +$1.27M 0.03% 519
2024
Q3 		$149K Sell
541
-432
-44% -$112K ﹤0.01% 1903
2024
Q2 		$236K Sell
973
-762
-44% -$120K ﹤0.01% 1938
2024
Q1 		$259K Sell
1,735
-4,937
-74% -$824K 0.01% 1244
2023
Q4 		$1.28M Buy
6,672
+1,582
+31% +$269K 0.02% 708
2023
Q3 		$901K Sell
5,090
-4,481
-47% -$855K 0.03% 580
2023
Q2 		$1.82M Buy
9,571
+8,895
+1,316% +$1.76M 0.06% 257
2023
Q1 		$135K Sell
676
-620
-48% -$130K ﹤0.01% 1604
2022
Q4 		$308K Sell
1,296
-1,573
-55% -$336K 0.01% 993
2022
Q3 		$575K Sell
2,869
-10,801
-79% -$2.06M 0.01% 1033
2022
Q2 		$1.99M Sell
13,670
-465
-3% -$66K 0.04% 375
2022
Q1 		$2.31M Buy
14,135
+7,404
+110% +$1.13M 0.02% 535
2021
Q4 		$1.14M Buy
6,731
+5,835
+651% +$1.08M 0.02% 629
2021
Q3 		$169K Sell
896
-1,182
-57% -$222K ﹤0.01% 1965
2021
Q2 		$352K Buy
2,078
+793
+62% +$116K 0.01% 1465
2021
Q1 		$181K Sell
1,285
-6,917
-84% -$1.04M ﹤0.01% 2094
2020
Q4 		$1.07M Buy
8,202
+3,874
+90% +$517K 0.03% 488
2020
Q3 		$631K Buy
4,328
+2,891
+201% +$411K 0.01% 1426
2020
Q2 		$213K Buy
1,437
+1,412
+5,648% +$190K 0.01% 1734
2020
Q1 		$3K Sell
25
-1,545
-98% -$178K ﹤0.01% 2438
2019
Q4 		$181K Buy
+1,570
New +$157K 0.02% 625
2019
Q3 		– Sell
-828
Closed -$60K – 4047
2019
Q2 		$60K Buy
828
+676
+445% +$51.9K ﹤0.01% 1482
2019
Q1 		$14K Buy
+152
New +$12.7K ﹤0.01% 2464
2018
Q4 		– Sell
-1,294
Closed -$113K – 3789
2018
Q3 		$113K Buy
1,294
+1,145
+768% +$115K 0.01% 1274
2018
Q2 		$15K Sell
149
-5,420
-97% -$538K ﹤0.01% 2576
2018
Q1 		$663K Buy
+5,569
New +$718K 0.06% 337
2017
Q1 		– Sell
-1,637
Closed -$61K – 2999
2016
Q4 		$61K Buy
1,637
+795
+94% +$33.3K 0.01% 1287
2016
Q3 		$57K Buy
+842
New +$59.4K 0.01% 1067
2016
Q2 		– Sell
-40
Closed -$3K – 4386
2016
Q1 		$3K Sell
40
-262
-87% -$17.4K ﹤0.01% 3040
2015
Q4 		$28K Buy
+302
New +$28K ﹤0.01% 935
2015
Q3 		– Sell
-389
Closed -$47K – 3940
2015
Q2 		$47K Buy
389
+162
+71% +$19.4K ﹤0.01% 1406
2015
Q1 		$24K Sell
227
-240
-51% -$24.3K ﹤0.01% 2094
2014
Q4 		$45K Sell
467
-16
-3% -$1.48K ﹤0.01% 1077
2014
Q3 		$38K Sell
483
-763
-61% -$49.2K ﹤0.01% 1771
2014
Q2 		$79K Sell
1,246
-1,198
-49% -$71.2K 0.01% 1026
2014
Q1 		$165K Buy
2,444
+1,954
+399% +$151K 0.02% 472
2013
Q4 		$32K Sell
490
-4,818
-91% -$287K 0.01% 1814
2013
Q3 		$340K Buy
5,308
+4,579
+628% +$228K 0.04% 453
2013
Q2 		$23K Buy
+729
New +$19.4K ﹤0.01% 1566

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s ALNY Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Alnylam Pharmaceuticals (ALNY) stake by 65% in Q1 2026, buying an estimated $1.29M and bringing the position to 9,627 shares worth $3.19M. The position accounts for 0.08% of the portfolio, ranked #245.

Tower Research Capital (TRC) first reported a position in ALNY in Q2 2013 and has held it in 44 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Tower Research Capital (TRC) held 9,627 shares of Alnylam Pharmaceuticals worth $3.19M as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,786 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.29M.
  • Alnylam Pharmaceuticals made up 0.08% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #245 holding.
  • Tower Research Capital (TRC) first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.